Drug intelligence / Profile preview

shark cartilage

Development stage
Phase 3
Lead developer
Æterna Zentaris
Modality
Recombinant Proteins and Enzymes
Administration
Oral, Topical (skin Application)
01

Overview

Shark cartilage is a dietary supplement derived from the cartilaginous tissue of sharks such as the spiny dogfish and hammerhead. It has been promoted for a variety of uses including cancer treatment and prevention, arthritis (osteoarthritis and rheumatoid arthritis), osteoporosis, psoriasis, macular degeneration, diabetic retinopathy, Kaposi sarcoma, wound healing, colitis and other inflammatory disorders. The proposed mechanism centers on its antiangiogenic properties—specifically inhibition of new blood vessel formation (angiogenesis) that tumors require for growth. This effect is thought to be mediated by glycoproteins such as sphyrnastatin 1 and 2 as well as other unidentified factors that interfere with endothelial cell migration/adhesion and inhibit matrix metalloproteinases (MMPs). Some formulations like Neovastat have shown in vitro inhibition of vascular endothelial growth factor (VEGF) binding/activity. Despite these mechanisms observed in preclinical studies or animal models—and anecdotal use—well-controlled clinical trials have not demonstrated efficacy for any indication in humans[1][6][9]. Shark cartilage is not approved by the FDA for any medical use; it is sold only as a dietary supplement.

Brand names
AE-941AE941AE 941NeovastatU995U-995U 995
Other names
shark cartilageSC
02

Targets

MMP9 (Matrix metalloproteinase-9)MMP14 (Matrix metalloproteinase 14)MMP13 (Matrix metalloproteinase-13)MMP2 (Matrix metalloproteinase-2)MMP1 (Matrix metalloproteinase-1)VEGFR2 (Vascular endothelial growth factor receptor 2)MMP3 (Matrix metalloproteinase-3)

Beyond the preview

Go deeper on shark cartilage.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on shark cartilage.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call